case_images: PMC10624449_01
case_images: Patient had primary myelofibrosis and underwent HCT from matched unrelated donor in March of 2020 with no acute or cGVHD. Patient received first dose of Pfizer vaccine in January 2021 and second dose in February 2021. Two weeks following the first dose of vaccine, he developed moderate to severe buccal and palatal mucosal erythema.
case_images: cro-2023-0016-0001-533821_F01.jpg
case_images: PMC10624449_01_cro-2023-0016-0001-533821_F01.jpg
case_images: F1
case_images: Two weeks following the first dose of vaccine he developed mouth soreness with moderate to severe buccal and palatal mucosal erythema (Fig. 1).
case_images: PMC10624449_02
case_images: Patient had secondary AML from prior myelofibrosis in June 2019 and underwent HCT from an unrelated donor with no acute or cGVHD. a In early February 2021 patient presented with mild oral GVHD. b Patient received first dose of Moderna vaccine (mRNA-1273) on February 16, 2021 and presented with prominent white lichenoid lesions on March 09, 2021. c Patient showed improvement in oral GVHD at subsequent visit on March 24, 2021.
case_images: cro-2023-0016-0001-533821_F02.jpg
case_images: PMC10624449_02_cro-2023-0016-0001-533821_F02.jpg
case_images: F2
case_images: When seen in early February 2021, he had oral changes consistent with mild oral GVHD (Fig. 2a). However, on March 09, 2021, he presented with oral sensitivity, and examination revealed prominent white lichenoid lesions (Fig. 2b) 1 month following the initial Moderna (mRNA-1273) vaccine on February 16, 2021. At his subsequent visit on March 24, 2021, oral examination showed improvement in oral GVHD (Fig. 2c).
case_images: PMC10624449_03
case_images: PMC10624449_04